It is widely accepted that inflammatory Bowel disease (IBD) arises from a dysregulated mucosal immune response to the enteric microbiota in the gut of a genetically susceptible individual. No definitive therapies are available for this inflammatory disorder. Therefore it became imperative to develop new strategies for treating this disease. Probiotics have emerged as a potential new therapeutic strategy for IBD, however their exact mechanisms of action is still poorly defined. In this study, we address the potential effect of a probiotic cocktail (Ultrabletique") composed of four live bacterial strains (L. acidophilus, L. plantarum, B. lactis and B.breve) to promote recovery from acute colitis. Probiotic was given to mice by oral gavage after the onset of colitis and the establishment of dextran sulfate sodium (DSS)-induced intestinal injury. Clinical parameters were monitored daily, histological scores of colitis and the production of nitric oxide (NO) and interferon-y (IFN-y) were determined. In addition, TLR4, NF-KB and iNOS colonic expression were examined. Probiotic treatment ameliorated clinical symptoms and histological scores. NO and IFN-y production in plasma were decreased by probiotic. These results were associated with reduced TLR4, iNOS and NF-KB expression in colonic tissue. In conclusion, probiotic exerted anti-inflammatory effects and contributed to a rapid recovery of DSS-induced acute colitis.
Inflammatory Bowel Disease (IBD) , which includes Crohn's disease (CD) and ulcerative colitis (UC), is a multifactorial chronic disorder of the intestinal tract characterized by period of relapse followed by remission (l). It is postulated that IBD arises from an impaired epithelial barrier leading to an exacerbated immune response to the resident microflora (2) . To maintain intestinal homeostasis, the innate immune system in the mucosa must be able to distinguish between commensal bacteria and pathogenic microorganisms without inducing local inflammation (3) . An inappropriate activation of innate immunity is strongly involved in the pathogenesis of IBD. Toll-Like Receptors (TLRs) are the first-line molecules of innate defense by recognizing conserved pathogen-associated molecular patterns (PAMPs) and endogenous signals or "danger signals" released from tissue injury. TLR4, one of the extensively characterized TLRs, is expressed by epithelial and immune cells such as dendritic cells, monocyte/macrophages and granulocytes. Activation of TLR4 by gram negative lipopolysaccharid (LPS) leads to the secretion of pro-inflammatory mediators in the intestinal mucosa, mainly through the activation of the transcription factor nuclear factor-B (NF-KB) (4) . Several studies on IBD patients and dextran sulfate sodium (DSS)induced experimental colitis have reported a high expression of TLR4 and NF-KB in the inflamed mucosa (5, 6) .
In IBD, evidence has been found for an overexpression of pro-inflammatory cytokines which contributes to the production of a large amount of Nitric oxide (NO). High levels of NO produced by inducible NOS have been related to cell and tissue injury during IBD (7) and experimental colitis (8) (9) (10) . Moreover, iNOS protein expression was shown to be increased within the inflammatory infiltrate of the lamina propria and epithelial cells in patients with IBD. It is known that iNOS is actively expressed under a verity of stimuli such as Interferon-v (IFN-y) and LPS. At the transcriptional level, iNOS is regulated by NF-KB (11-12).
Because the exact pathogenesis ofIBD is partially elucidated, no definitive therapies are available for this inflammatory disorder. Conventional treatments for IBD rely on salazosulfamide, glucocorticoids and immunosuppressive agents. However, these therapies are not always effective and are often complicated by significant adverse effects, indicating the need for new therapeutics with lower sideeffect risk (13) . Therefore, there is an increasing interest in developing new therapeutic approaches such as probiotics. They are described as "live microorganisms which, when ingested in sufficient numbers, convey health benefits to the host" (14) . Current data, obtained mainly from animal models of colitis studies, suggest that probiotics such as Bifidobacterium and Lactobacillus improve barrier function and preserve the intestinal epithelial barrier (10, 15) .
Ou team has developed great interest in using probiotics as new therapeutic agents. In our previous studies using a DSS-induced experimental model of colitis in mice, we reported a preventive effect of a probiotic cocktail before and during the onset of DSS-induced colitis (9) (10) . However, to our knowledge, few studies have reported the effect of probiotic after the onset of experimental colitis. In the present study, we assumed that Ultrabiotique" probiotic composed of four live bacterial strains, 1. acidophilus, 1. plantarum, B. lactis andB. breve, may accelerate recovery from acute symptoms of colitis and intestinal tissue damages. We investigated its effect on intestinal expression of TLR4, NF-KB and iNOS to further shed light on the underlying mode of action of probiotics still poorly defined.
MATERIALS AND METHODS
Eight-week-old female BALB/c mice were purchased from the Pasteur Institute (Algiers, Algeria). They were housed in a 12-h light and 12-h dark cycle with free access to food and water. After 7 days of acclimatization, the mice were randomly divided into the following treatment groups (n=6-12 mice per group); controls (Ctrl), dextran sulfate sodium (DSS), probiotics (Prb) and dextran sulfatesodium+probiotics (DSS+Prb) (Fig.  1 ). The control group received tap water. The DSS model group received 3% (w/v) of DSS in their drinking water ad libitum for 5 days in order to induce acute colitis followed by 5 days of tap water for the recovery. The DSS+Prb group received 3% (w/v) of DSS for 5 days and 10 9 CFU/ml of probiotic for 7 days starting from day 3 to the end of the experimental period. The Prb group received 10 9 CFU/ml of probiotic for 7 days starting from day 3. The mice were fed with 200 ul, of daily-prepared suspension of the probiotic formula in skimmed milk by oral gavage. The arrow in Fig. 1 shows the day when mice were sacrificed. The probiotic Ultrabiotique", which is produced by Laboratoire Nutrisante (Montaigu-France), consists offour lyophilized bacterial strains: Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium lactis and Bifidobacterium breve, and was dissolved in skimmed sterile milk and diluted to a concentration of 10 9 CFU/ml.
Survival measurement, body weight and Disease activity scores (DAI)
To assess the effect of probiotic treatment on mice, survival, body weight of the animals and the clinical course of colitis were monitored daily over the course of the experiment period. Body weight change for each individual mouse was calculated as follows: Percent weight change = [(weight at specific day-weight on Day O)/weight on Day 0) X100]. The disease activity index (DIA) scores body weight loss, stool consistency, and rectal bleeding as described by Murthy et al. (16) . In brief, each score in DAI was determined as the extent of body weight loss (0 <1%; 1: 1-5%; 2: 5-10%; 3: 10 a20%; 4> 20%), stool consistency (0, normal; 2, loose; 4, diarrhea), and gross bleeding (0, normal color; 2, reddish color; 4, bloody stool) and combined and divided by 3 for each mouse. Mice that became moribund were euthanized.
Blood collection
All mice were sacrificed after 10 days by deep anesthesia and blood samples were obtained by cardiac puncture. They were collected in EDTA-coated tubes then centrifuged lit 3000 xg for 10 min to obtain plasma. All. plasma samples were kept at -20°C for subsequent nitrite measurement and IFN-y secretion assay.
Analysis ofcolon inflammation
The colon, from the ileo-caecal junction to the anus was excised. The length and weight ofcolons as an indirect marker of inflammation were measured, and rinsed with sterile PBS, pH 7.4 to remove the fecal remnants. Sections from distal colon were harvested and fixed in 10% phosphate-buffered formalin, dehydrated and embedded in paraffin. These samples were sectioned at 4 urn, and stained with H&E for light microscopic examination. Assessment of histological score was blindly determined on formalin-fixed and paraffin-embedded sections stained with hematoxylin and eosin as previously described (17) . In brief, for tissue inflammation, occasional cell infiltrate in the lamina propria was scored as 0, cell infiltration predominantly at the base of the crypt was scored as 1, cell infiltration extending to the mucosa was scored as 2 and transmural infiltration was scored as 3. For tissue damage, no damage was scored as 0, up to 50% loss of the crypts was scored as 1, 50-100% loss of the crypts with epithelium intact was scored as 3 and total loss ofthe crypts with epithelium lost was scored as 3. The combined histological colitis severity score ranged from 0 to 6.
Mouse colon organ culture
The colon explants were cut into 3-mm segments and weighed. They were cultured in DMEM containing 10% FBS, 1% penicillin-streptomycin at 37°C with 5% C02 for 20 hours. Supernatants were then collected for nitrite measurement. Nitrite concentrations were normalized to the weight of each colonic explant.
Nitrite determination
Nitrite (N02') concentrations, a measure of NO synthesis, was assayed on the basis of modified Griess reaction as described by Touil-Boukoffa et al. (18) . In brief, 50 III of plasma or colon explant supernatants were mixed with 50 III of Griess reagent (5% sulfanilamide, 0.5% napthylethylenediamine dihydrochloride and 20% HCI) and 400 ul, of distilled water. The resulting solution was incubated for 20 min at room temperature. Absorbance was assayed at 543 nm and compared with a standard curve obtained using sodium nitrite (NaN0 2).
Cytokine assay
The concentrations ofIFN-y in plasma were measured by enzyme-linked immunosorbent assay (ELISA) kit for mice according to the manufacturer's instructions (Invitrogen Life Technologies).
Immunofluorescent and immunohistochemical studies
Paraffin-embedded colon sections were deparaffinized, rehydrated and subjected to antigen retrieval by boiling in the appropriate buffer. After unmasking antigens, colon, sections were incubated with 5% of skim milk. For the immunofluorescent study, colon sections were stained with anti-TLR4 antibody (Invitrogen Life Technologies; diluted 1:100) overnight at 4°C and FITC-labeled secondary antibody (Invitrogen Life Technologies; diluted 1:1000) for 1 h at room temperature. Sections were then mounted with mounting medium and observed by fluorescence microscopy. For immunohistochemistry study, colon sections were stained with an anti-iNOS 
RESULTS

Probiotic treatment reduced clinical indexes of (DSS)-induced acute colitis
To determine the ability ofprobiotic to ameliorate established colitis, mice were treated with 3% ofDSS for 5 days to induce colitis. DSS was then replaced with regular drinking water for 5 days for the recovery period. 10 9 UFC/ml of probiotic was given to mice by oral gavage at day 3 concomitantly with DSS administration and continued during the recovery period until the end of the study (day 10) ( Fig. 1 ). As shown in Fig. 2A , treating mice with probiotic after the onset of colitis delayed DSS-induced mortality.
There was substantially less mortality with probiotic supplementation as survival improved from 50% in the DSS group to 81.25% in the DSS+Prb group. In the DSS and DSS+Prb groups, the mice began to lose body weight after 5 days of DSS treatment. The body weight loss continued during the recovery period in colitic mice. However, in the DSS+Prb group the weight loss became stabilized and was significantly different compared to the DSS group (**p<O.Ol) ( Fig. 2B) . Moreover, treatment ofmice with probiotic resulted in rapid resolution of diarrhea and blood loss. The difference in the DAI score, an indicator of the severity of mucosal intestinal inflammation, was highly significant between the DSS and DSS+Prb groups (*p <0.05) (Fig. 2C) .
Probiotic supplementation promoted recovery of (DSS)-induced intestinal injury and inflammation in BALBk mice
The high DAI score and the decrease in body weight observed in the DSS group were accompanied by gross morphological changes in colon. The colon length of DSS-treated mice with probiotic was significantly longer than that of the DSS group (***p<O.OOI). No Significant difference was observed in the colon length of the DSS+Prb group and the Ctrl group (Fig. 3A) . The same pattern was observed for the weight of colon which was
Fig. 4. Representative histological images of an H&E-stain ed paraffin section of colonic tissue from mouse of each experimental group. Mice given DSS had complete mucosal destruction (asterisk) and irflammatory infi ltration in the mucosa andsub mucosa (arrow). The DSS+Prb group had improved colitis scores with areas ofsurf ace re-epithelialization (arrowhead) and cryp ts regeneration (double arrow) . M: mucosa; SM' Sub Mucosa (DSS group (n=6). DSS+Prb group (n=8), Prb goup (n=6), Ctrl gtoup (n=6) .
lower in DSS+Prb group compared to DSS group (*p<O.05) ( Fig . 3B ). Histological damage was evaluated by the scoring method described above in Materials and Methods. It revealed high histological scores in the DSS group (Fig. 3C) with an active colitis characterized by complete tissue destruction of the crypts, goblet cell depletion and a severe loss of epithelial layer. Moreover, mucosal and submucosal heterogeneous inflammatory infiltration was observed. Interestingly, tissue samples from mice with DSS-induced colitis treated with probiotic had significantly improved colitis scores (*p<O.05), showing well-preserved crypts structures, decreased number of infiltrating cells and intact epithelial cells layer reflecting re-epithelialization and tissue repair ( Fig. 4) .
Probiotic supplem entation reduced nitrite levels in plasma and colonic explant culture ofDSS-induced acute colitis
Excessive production of nitric oxide (NO) has been implicated in tissue damages and mucosal lesions observed during IBD (14) . In light of the results obtained from histological analysis showing lower histological damage score of mucosa in mice treated with probiotic, we investigated NO production in the plasma and culture supernatants of colonic explants. As shown in Fig. 5, A and B , nitrite levels of the DSS group were significantly higher in plasma (****p<O.OOOl) and culture supernatants of colon explants (*p<O.05) when compared to the control group. Interestingly, mice from the DSS+Prb group showed a highly significant decrease of nitrite levels in plasma (***p<O.OOI) and culture supernatants of colonic explants (***p<O.OOI) compared to the DSS group. No significant difference was observed between the Prb and Ctrl groups either in plasma or culture supernatants of colonic explants.
Plasmatic IFN-y production levels in DSSinduced acute colitis was reduced after probiotic supplementation
As IFN-y is a potent inducer of NO generation, we investigated whether probiotic supplementation affects its production by ELISA assay in plasma. As expected, colitic mice showed a high production of IFN-y (26.51±6.04pglml, *p<O.05) compared to the Ctrl group (10.23±3.42pg/ml), whereas probiotic treatment in theDSS+Prb group caused a significant decrease of IFN-y in plasma (lO.93±l.Olpg/ml, *p<O.05) which was similar to the Ctrl group (Fig.  5C ). No significant difference was observed between the Prb (4.l8±1.86 pg/ml) and Ctrl groups.
Probiotic treatment reduced TLR4 expression in distal colon of(DSS)-induced acute colitis
Numerous studies have demonstrated that IFN-y and LPS act in a synergistic fashion to induce iNOS expression and NO production (19) . High expression of TLR-4 found in epithelial cells of IBD patients (5) suggests a potentially increased responsiveness to LPS which leads to activation ofNF-kB and the transcription of pro-inflammatory genes. In our study, immunofluorescent staining for TLR4 in distal colon of colitic mice (Fig. 6C ) was abundantly 
Fig. 7. Immunohistochemical detection of iNOS and NF-KB in distal colon of DSS-induced acute colitis. iNOS and NF-KB expression was increased in the mucosa and submucosa ofDSS treated mice but was reduced in the mucosa of mice treated by probiotic. iNOS: A) Ctrl group (n=6). B) Prb group (n=6) (xlO). C, D) DSS group (n=8) (xl t), x40). E, F) DSS+Prb group (n=lO) (x lO, x40). NF-KB: G) Ctrl group. H) Prb group(xlO). I, J) DSS group (xlO. x40). K, L) DSS +Prb group (xlO, x40) (arrows: positive immunostaining).
positive in mucosa compared to the Ctrl group (Fig.  6A ). In addition, not only did TLR4 expression increase in the mucosa, but it was also observed in the submucosa where there was a marked infiltration of immune cells (Fig. 6D) . Samples from the DSS+Prb group showed weaker positivity ofTLR4 staining in the mucosa and a notable decrease in the sub mucosa.
However, a few TLR4 positive cells were detected at the base of the crypt. Interestingly, no difference was noticed between the Prb group (Fig. 6B ) and the Ctrl group. These data suggest that the effect of the probiotic supplementation in promoting recovery from DSS-acute colitis and attenuation of intestinal inflammation may be mediated by down-regulation ofTLR-4 expression.
Probiotic treatment reduced expression ofiNOS and NF-KB in distal colon ofDSS-induced acute colitis
One of the major sources of iNOS-derived NO in IBD and experimental colitis is infiltrating macrophages in the colonic tissue probably due to the important bacterial translocation and endotoxin exposure. Our results showed a marked inflammatory cell infiltration after DSS treatment associated with high plasma levels of NO and IFN;:'y as well as an over expression ofTLR4 in the distal colon. Because iNOS is an NF-KB-mediatedprotein, we examined the effect ofprobiotic on iNOS and NF-KB expression in (DSS)-induced acute colitis. Sections from the same colonic tissues showed staining for iNOS and NF-KB in DSS group (Fig. 7) . Positive staining was found throughout the mucosa ( Fig. 7 , C, I) but was very intense in submucosal inflammatory cells ( Fig. 7 , D, J). As expected, localization of positive staining for iNOS and NF-KB coincides with those ofTLR4 (Fig.  6 ). No iNOS staining was observed in the Ctrl or Prb groups whereas a minimal NF-KB expression was noted in the Ctrl and Prb groups. On the other hand, colon sections from colitic mice treated by probiotic showed generally weak staining for iNOS and NF-KB ( Fig. 7, F, L) .
DISCUSSION
The conventional therapies for IBD have been targeted only toward the deregulated mucosal immune response. Therefore, it became imperative to develop new complementary strategies which operate both on modulating immune-inflammatory responses and repairing damaged epithelial layer. Because probiotics meet these criteria, they have emerged as a potential new therapeutic strategy for IBD. Probiotic therapy has been effective in maintenance of remission of pouchitis, Crohn's disease, and ulcerative colitis (20) .
In the study outlined here, probiotic supplementation for a therapeutic purpose was initiated at day 3. At this point of DSS treatment, it has been well established that mice exhibit clinical symptoms of colitis which reflect the onset of inflammation and histological damage (21) (22) . Similar clinical patterns of colitis were observed in our study. Probiotic supplementation after the onset of colitis and during the recovery period strongly decreased the clinical symptoms and gross morphological changes in the colon. Moreover, clear signs of tissue repair, including re-epithelialization and crypts regeneration, were evident in mice treated with probiotic. These data indicate that probiotic treatment may be effective in promoting rapid recovery from colitis and restoring the colonic epithelium after DSS treatment.
In the current study, histological analysis revealed the presence ofheterogeneous inflammatory infiltrate. These immune cells promote the secretion of proinflammatory cytokines and nitric oxide. Numerous studies showed that chronic inflammation observed in IBD, is associated with prolonged activation of iNOS and a strong production of NO. The latter contribute to the perpetuation of inflammation causing tissue damage (23) . Our data indicated a significant NO level increase both in plasma and in the culture supernatants of colon explants of the DSS group. These results correlated with a high level ofIFN-y production in plasma. In our study we focused on the effects of probiotic during the acute phase ofDSS colitis in which a major neutrophil and macrophage cell infiltrate was observed. However, in other published studies a clear involvement of lymphocytes and IFN-y in the initiation of DSS colitis has been demonstrated (24) . Besides, IFN-y greatly enhances nitric oxide production through transcription of iNOS when added to LPS (19) . In the same line, our results showed high expression of TLR4, iNOS and NF-KB in colonic tissue ofthe DSS group.. Nitric oxide produced by the inducible NO synthase (iNOS) is a critical component of host defenses against bacteria. Therefore, the presence of a high rate of NO in the local and systemic level may indicate the presence of microbial agonists. Administration of DSS in the drinking water of mice alters the integrity of the intestinal epithelial barrier and promotes translocation of enteric bacteria and pathogens. TLR4 activation by enteric bacteria and endotoxins, has been implicated in inflammatory bowel diseases pathogenesis. The exact role ofTLR4 in intestinal inflammation is still a matter of controversy. However, in line with our findings, several studies showed a high expression of TLR4 during intestinal inflammation, whereas it is generally low in normal human colon tissue. Intestinal epithelial cells have the potential to upregulate the expression of TLRs following proinflammatory cytokine signals and other stimuli. It has been shown that IFN-y could markedly enhance the sensitivity of IEC response to LPS through the transcriptional induction ofTLR4 and its co-receptor (MD-2) (25) . The triggering of TLR4 complex signaling by LPS induces an intracellular signaling cascade that leads to the activation ofNF-KB which enhances the transcription of iNOS. In the present study, we addressed the effect of probiotic on TLR4 expression. In concordance with others (26), our results suggests that probiotics can affect TLR4 expression in a down-regulatory fashion Interestingly, probiotic supplementation to colitic mice after the onset of colitis and during the recovery period significantly reduced production of NO in plasma and culture supernatants of colon explants . and decreased the expression of iNOS and NF-KB in colonic tissues. Moreover, a significant decrease of IFN-y in plasma was observed. Numerous studies reported the ability of probiotics to down-regulate pro-inflammatory cytokine production and to upregulate anti-inflammatory cytokines such as IL-IO and TGF -~by mononuclear cells in the lamina propria (27) . Fitzpatrick et al. (28) showed that the probiotic Escherichia.coli strain Ml7 exerts anti-inflammatory effects in DSS-induced colitis through inhibition of pro-inflammatory cytokine secretion: IL-6, IL-Iã nd TNF-a. The improvement of murine colitis was probably due to an inhibitory effect of E.coli-MI7 on NF-kB signaling. Thus, it appears that the antiinflammatory effects of probiotics are associated in most studies, including our work, to the activity of the transcription factor NF-KB which is enhanced in the inflamed intestinal mucosa of patients with IBD and in experimental models of colitis (29) . Probiotics can alter NF-KB pathway at many different levels: degradation and ubiquitination and inhibition of proteasome function. Induction of the nuclear export of complexes formed by nuclear factor (NF)-kB and peroxisome proliferator-activated receptor-y (PPAR-y) is another anti-inflammatory mechanism induced by probiotics (23) .
In conclusion, our data support and extend our hypothesis that the probiotic used (Ultrabiotique®) has not only beneficial effects on the maintenance of integrity of the epithelial barrier and tissue repair (9-10) but has also anti-inflammatory effects. Probiotic administration effectively promoted recovery from acute colitis by improving clinical symptoms and histological score. The results suggest that the probiotic used herein (Ultrabiotique") affords therapeutic advantages and may be a good candidate in the treatment ofIBD.
